The TEA 2/16 monoclonal antibody specifically recognizes CD109 which is also known as C3 and PZP-like alpha-2-macroglobulin domain-containing protein 7 (CPAMD7), Gov platelet alloantigens, or 150 kDa TGF-beta-1-binding protein. CD109 is a 150-170 kDa glycosylphosphatidylinositol (GPI)-linked glycoprotein expressed on activated T cells, myeloid progenitor (CD34+) and mature myeloid lineage cells (monocytes, granulocytes, platelets), but not on CD34+ lymphoid progenitor cells. CD109 is also expressed on vein and artery endothelial cells. The expression of CD109 is upregulated on PHA-stimulated T cells. CD109 is reportedly expressed on long-term adult bone marrow cultured cells, where it is co-expressed with CD34 and CD90. Its biological role in hematopoiesis has not been fully elucidated. It may play a role in the negative regulation of transforming growth factor beta receptor signaling.
The antibody was conjugated to BD Horizon™ BB700, which is part of the BD Horizon Brilliant™ Blue family of dyes. It is a polymer-based tandem dye developed exclusively by BD Biosciences. With an excitation max of 485 nm and an emission max of 693 nm, BD Horizon BB700 can be excited by the 488 nm laser and detected in a standard PerCP-Cy™5.5 set (eg, 695/40-nm filter). This dye provides a much brighter alternative to PerCP-Cy5.5 with less cross laser excitation off the 405 nm and 355 nm lasers.